Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents

被引：41

作者：

Korn, EL ^{[1
]}

机构：

[1] NCI, Biometr Res Branch, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2004年 / 96卷 / 13期

关键词：

D O I：

10.1093/jnci/djh208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：977 / 978

页数：2

共 10 条

[1] Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily [J].

Eder, JP ;

Supko, JG ;

Clark, JW ;

Puchalski, TA ;

Garcia-Carbonero, R ;

Ryan, DP ;

Shulman, LN ;

Proper, J ;

Kirvan, M ;

Rattner, B ;

Connors, S ;

Keogan, MT ;

Janicek, MJ ;

Fogler, WE ;

Schnipper, L ;

Kinchla, N ;

Sidor, C ;

Phillips, E ;

Folkman, J ;

Kufe, DW .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3772-3784

[2] Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? [J].

Gelmon, KA ;

Eisenhauer, EA ;

Harris, AL ;

Ratain, MJ ;

Workman, P .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (15) :1281-1287

[3] Phase I study of recombinant human endostatin in patients with advanced solid tumors [J].

Herbst, RS ;

Hess, KR ;

Tran, HT ;

Tseng, JE ;

Mullani, NA ;

Charnsangavej, C ;

Madden, T ;

Davis, DW ;

McConkey, DJ ;

O'Reilly, MS ;

Ellis, LM ;

Pluda, J ;

Hong, WK ;

Abbruzzese, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3792-3803

[4] Clinical trial designs for cytostatic agents: Are new approaches needed? [J].

Korn, EL ;

Arbuck, SG ;

Pluda, JM ;

Simon, R ;

Kaplan, RS ;

Christian, MC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :265-272

[5] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[6]

Paez J.G., 2004, SCIENCE

[7] Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice [J].

Parulekar, WR ;

Eisenhauer, EA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (13) :990-997

[8] Novel endpoints and design of early clinical trials [J].

Parulekar, WR ;

Eisenhauer, EA .

ANNALS OF ONCOLOGY, 2002, 13 :139-143

[9] Development of target-based antineoplastic agents [J].

Stadler, WM ;

Ratain, MJ .

INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) :7-16

[10] Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors [J].

Thomas, JP ;

Arzoomanian, RZ ;

Alberti, D ;

Marnocha, R ;

Lee, F ;

Friedl, A ;

Tutsch, K ;

Dresen, A ;

Geiger, P ;

Pluda, J ;

Fogler, W ;

Schiller, JH ;

Wilding, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :223-231

← 1 →